Table 3

Impact of disease and treatment on patient day-to-day limitation

Occupation or Job

Daily activities

Lifestyle


Group Mean (SD)

2.11

(1.35)

2.25

(1.24)

2.45

(1.25)


Adjusted R2 (N)

0.17

(512)

0.17

(512)

0.18

(512)


Age

0.03(.04)

0.12(.04)

**

0.06(.04)


AntiD aggregate bother interaction †

0.20(.05)

****

0.16(.04)

***

0.14(.04)

**


CS aggregate bother interaction †

0.12(.04)

**

0.11(.04)

*

0.09(.04)

*


IVIg aggregate bother interaction †

0.21(.05)

****

0.15(.05)

**

0.17(.05)

**


Rituximab aggregate bother interaction †

0.17(.05)

***

0.12(.05)

*

0.12(.05)

*


Splenectomy aggregate bother interaction †

0.20(.05)

***

0.19(.05)

***

0.17(.05)

***


Frequency of dry bleeds (0 = No bleeds, 1 = bleeds)

0.05(.05)

0.13(.05)

**

0.15(.05)

**


Time since last taking drug/procedure§

0.02(.04)

-0.04(.04)

-0.02(.04)


Gender (0 = male; 1 = female)

-0.06(.04)

-0.06(.04)

-0.05(.04)


Typical low platelet count (past year)

-0.12(.06)

*

-0.12(.06)

*

-0.11(.05)

*


Number of ITP treatments (among 5 treatment types)

-0.17(.07)

**

-0.12(.07)

-0.09(.04)


Type of physician ‡

-0.05(.04)

0.04(.04)

0.00(.05)


Frequency of wet bleeds (0 = No bleeds, 1 = bleeds)

0.13(.05)

**

0.13(.05)

**

0.17(.04)

***


* P <0.05

* *P <0.01

* **P <0.001

* ***P <0.0001

Each model based on all patients. Patients with no side effects for a given treatment type were coded as 1.

† Interaction term = Aggregate bother (1-5) × treatment received (0,1)

‡ Type of physician referred to generalist or specialist

§ Categorical variable were 0 = Currently taking (Less than 5 years ago in case of splenectomy), 1 = Taken in the past (5 or more years ago in case of splenectomy)

Brown et al. BMC Blood Disorders 2012 12:2   doi:10.1186/1471-2326-12-2

Open Data